Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis

This abstract from the 2017 American Society of Hematology Annual Meeting supports LCL161 as a potential promoter of apoptosis in patients with myelofibrosis, including those with JAK inhibitor–refractory disease.

 Blood (ASH Abstract)

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.